Pharmacokinetics I: PK-PD approach, the case of antibiotic drug development

Clinical Pharmacology: Current Topics and Case Studies: Second Edition

Volumn , Issue , 2016, Pages 185-217

  Sy, Sherwin K B ^a,b,c   Derendorf, Hartmut ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b STATE UNIVERSITY OF MARINGÁ   (Brazil)

^c NEKTAR THERAPEUTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84976902403     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-27347-1_13     Document Type: Chapter

References (165)

1. Andes D, Craig WA (2002) Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 19:261-268
2. Begg EJ, Barclay ML, Duffull SB (1995) A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 39:605-609
3. Moise PA, Forrest A, Bhavnani SM, Birmingham MC, Schentag JJ (2000) Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm 57(Suppl 2):S4-S9
4. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ (2004) Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 43:925-942
5. Asin-Prieto E, Rodriguez-Gascon A, Isla A (2015) Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents. J Infect Chemother 21:319-329
6. Liu P, Muller M, Derendorf H (2002) Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. Int J Antimicrob Agents 19:285-290
7. Tawara S, Matsumoto S, Kamimura T, Goto S (1992) Effect of protein binding in serum on therapeutic efficacy of cephem antibiotics. Antimicrob Agents Chemother 36:17-24
8. Wu B, Sy SK, Derendorf H (2014) Principles of applied pharmacokinetic-pharmacodynamic modeling. In: Vinks AA, Derendorf H, Mouton JW (eds) Fundamentals of antimicrobial pharmacokinetics and pharmacodynamics. Springer, New York, pp 63-79
9. Sy SK, Wang X, Derendorf H (2014) Introduction to pharmacometrics and quantitative pharmacology with an emphasis on physiologically based pharmacokinetics. In: Derendorf H, Schmidt S (eds) Applied pharmacometrics. Springer, New York, pp 1-64
10. de Kock L, Sy SK, Rosenkranz B, Diacon AH, Prescott K, Hernandez KR et al (2014) Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis. Antimicrob Agents Chemother 58:6242-6250
11. Shilbayeh SA, Sy SK, Melhem M, Zmeili R, Derendorf H (2015) Quantitation of the impact of CYP3A5 A6986G polymorphism on quetiapine pharmacokinetics by simulation of target attainment. Clin Pharmacol Drug Dev 4:323-399
12. Mouton JW, Brown DF, Apfalter P, Canton R, Giske CG, Ivanova M et al (2012) The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clin Microbiol Infect 18:E37-E45
13. Mouton JW, Punt N, Vinks AA (2005) A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit. Clin Ther 27:762-772
14. Sy SK, Derendorf H (2014) Pharmacometrics in bacterial infections. In: Schmidt S, Derendorf H (eds) Applied pharmacometrics, 1st edn. Springer, New York, pp 229-258
15. Zhuang L, Xia H, He Y, Liu Y, Sy SK, Derendorf H (2016) Gentamicin dosing strategy in patients with end-stage renal disease receiving hemodialysis: evaluation using a semi-mechanistic pharmacokinetic/pharmacodynamic model. J Antimicrob Chemother (Forthcoming)
16. Zhuang L, Sy SK, Xia H, Singh RP, Mulder MB, Liu C et al (2015) Evaluation of in vitro synergy between vertilmicin and ceftazidime against Pseudomonas aeruginosa using a semi-mechanistic pharmacokinetic/pharmacodynamic model. Int J Antimicrob Agents 45:151-160
17. Ungerstedt U, Pycock C (1974) Functional correlates of dopamine neurotransmission. Bull Schweiz Akad Med Wiss 30:44-55
18. Muller M, dela Pena A, Derendorf H (2004) Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother 48:1441-1453
19. Plock N, Kloft C (2005) Microdialysis - theoretical background and recent implementation in applied life-sciences. Eur J Pharm Sci 25:1-24
20. Traunmuller F, Zeitlinger M, Zeleny P, Muller M, Joukhadar C (2007) Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. Antimicrob Agents Chemother 51:3185-3189
21. Barbour A, Schmidt S, Rout WR, Ben-David K, Burkhardt O, Derendorf H (2009) Soft tissue penetration of cefuroxime determined by clinical microdialysis in morbidly obese patients undergoing abdominal surgery. Int J Antimicrob Agents 34:231-235
22. Hutschala D, Skhirtladze K, Kinstner C, Mayer-Helm B, Muller M, Wolner E et al (2007) In vivo microdialysis to measure antibiotic penetration into soft tissue during cardiac surgery. Ann Thorac Surg 84:1605-1610
23. Pankey GA, Sabath LD (2004) Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin Infect Dis 38:864-870
24. Craig WA (2014) In vitro and animal PK/PD models. In: Vinks AA, Derendorf H, Mouton JW (eds) Fundamentals of antimicrobial pharmacokinetics and pharmacodynamics. Springer, New York, pp 23-44
25. Peterson LR, Shanholtzer CJ (1992) Tests for bactericidal effects of antimicrobial agents: technical performance and clinical relevance. Clin Microbiol Rev 5:420-432
26. Fernandes PB, Bailer R, Swanson R, Hanson CW, McDonald E, Ramer N et al (1986) In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. Antimicrob Agents Chemother 30:865-873
27. Piscitelli SC, Danziger LH, Rodvold KA (1992) Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm 11:137-152
28. Retsema J, Girard A, Schelkly W, Manousos M, Anderson M, Bright G et al (1987) Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother 31:1939-1947
29. Nastro LJ, Finegold SM (1972) Bactericidal activity of five antimicrobial agents against Bacteroides fragilis. J Infect Dis 126:104-107
30. Bostic GD, Perri MB, Thal LA, Zervos MJ (1998) Comparative in vitro and bactericidal activity of oxazolidinone antibiotics against multidrug-resistant enterococci. Diagn Microbiol Infect Dis 30:109-112
31. Zurenko GE, Yagi BH, Schaadt RD, Allison JW, Kilburn JO, Glickman SE et al (1996) In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 40:839-845
32. Hoyne AL, Simon DL (1953) Intramuscular terramycin in treatment of meningitis: report of 21 recoveries. Arch Pediatr 70:319-325
33. Paredes A, Taber LH, Yow MD, Clark D, Nathan W (1976) Prolonged pneumococcal meningitis due to an organism with increased resistance to penicillin. Pediatrics 58:378-381
34. Shaikh ZH, Peloquin CA, Ericsson CD (2001) Successful treatment of vancomycin-resistant Enterococcus faecium meningitis with linezolid: case report and literature review. Scand J Infect Dis 33:375-379
35. Zeana C, Kubin CJ, Della-Latta P, Hammer SM (2001) Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature. Clin Infect Dis 33:477-482
36. Levitz RE, Quintiliani R (1984) Trimethoprim-sulfamethoxazole for bacterial meningitis. Ann Intern Med 100:881-890
37. Nemeth J, Oesch G, Kuster SP (2015) Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: systematic review and meta-analysis. J Antimicrob Chemother 70:382-395
38. Crandon JL, Nicolau DP (2013) Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-beta-lactamase producers. Antimicrob Agents Chemother 57:3299-3306
39. Sy SK, Beaudoin ME, Nichols WW, Schuck VJ, Derendorf H (2014) Avibactam and ceftazidime combination against multidrug resistant organisms in an in vitro pharmacokinetic/ pharmacodynamic model. In: 54th Interscience conference of antimicrobial agents and chemotherapy. Washington, DC, pp abstr A-1344
40. Sy SK, Beaudoin ME, Schuck VJ, Derendorf H (2013) Modeling the potentiation of in vitro aztreonam activities by avibactam against four beta-lactam-resistant bacterial strains. In: 53rd Interscience conference of antimicrobial agents and chemotherapy. Denver, pp abstr A-1014
41. Ly NS, Bulitta JB, Rao GG, Landersdorfer CB, Holden PN, Forrest A et al (2015) Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance. J Antimicrob Chemother 70:1434-1442
42. Blaser J, Stone BB, Zinner SH (1985) Two compartment kinetic model with multiple artificial capillary units. J Antimicrob Chemother 15(Suppl A):131-137
43. Blaser J, Stone BB, Zinner SH (1985) Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model. Antimicrob Agents Chemother 27:343-349
44. Zinner SH, Husson M, Klastersky J (1981) An artificial capillary in vitro kinetic model of antibiotic bactericidal activity. J Infect Dis 144:583-587
45. Michael J, Barth A, Kloft C, Derendorf H (2014) Pharmacodynamic in vitro models to determine the effect of antibiotics. In: Vinks AA, Derendorf H, Mouton JW (eds) Fundamentals of antimicrobial pharmacokinetics and pharmacodynamics. Springer, New York, pp 81-112
46. Ba BB, Bernard A, Iliadis A, Quentin C, Ducint D, Etienne R et al (2001) New approach for accurate simulation of human pharmacokinetics in an in vitro pharmacodynamic model: application to ciprofloxacin. J Antimicrob Chemother 47:223-227
47. Louie A, Grasso C, Bahniuk N, Van Scoy B, Brown DL, Kulawy R et al (2010) The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression. Antimicrob Agents Chemother 54:2646-2654
48. Drusano GL, Sgambati N, Eichas A, Brown DL, Kulawy R, Louie A (2010) The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model. MBio 1: e00139-10
49. Kim A, Banevicius MA, Nicolau DP (2008) In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. Antimicrob Agents Chemother 52:2497-2502
50. Andes D, Craig WA (1998) In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother 42:2375-2379
51. Nicolau DP, Onyeji CO, Zhong M, Tessier PR, Banevicius MA, Nightingale CH (2000) Pharmacodynamic assessment of cefprozil against Streptococcus pneumoniae: implications for breakpoint determinations. Antimicrob Agents Chemother 44:1291-1295
52. Kunst MW, Mattie H (1978) Cefazolin and cephradine: relationship between antibacterial activity in vitro and in mice experimentally infected with Escherichia coli. J Infect Dis 137:391-402
53. Gerber AU, Craig WA, Brugger HP, Feller C, Vastola AP, Brandel J (1983) Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice. J Infect Dis 147:910-917
54. Zuluaga AF, Salazar BE, Rodriguez CA, Zapata AX, Agudelo M, Vesga O (2006) Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases. BMC Infect Dis 6:55
55. Craig WA (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1-10; quiz 1-2
56. Craig WA (2001) Does the dose matter? Clin Infect Dis 33(Suppl 3):S233-S237
57. Kovar A, Dalla Costa T, Derendorf H (1997) Comparison of plasma and free tissue levels of ceftriaxone in rats by microdialysis. J Pharm Sci 86:52-56
58. Liu P, Fuhrherr R, Webb AI, Obermann B, Derendorf H (2005) Tissue penetration of cefpodoxime into the skeletal muscle and lung in rats. Eur J Pharm Sci 25:439-444
59. Crandon JL, Schuck VJ, Banevicius MA, Beaudoin ME, Nichols WW, Tanudra MA et al (2012) Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa. Antimicrob Agents Chemother 56:6137-6146
60. Housman ST, Crandon JL, Nichols WW, Nicolau DP (2014) Efficacies of ceftazidime-avibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection model. Antimicrob Agents Chemother 58:1365-1371
61. Mangoni AA, Jackson SH (2004) Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 57:6-14
62. Wooten JM (2012) Pharmacotherapy considerations in elderly adults. South Med J 105:437-445
63. Hollenberg SM, Ahrens TS, Annane D, Astiz ME, Chalfin DB, Dasta JF et al (2004) Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med 32:1928-1948
64. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B et al (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368-1377
65. Rackow EC, Falk JL, Fein IA, Siegel JS, Packman MI, Haupt MT et al (1983) Fluid resuscitation in circulatory shock: a comparison of the cardiorespiratory effects of albumin, hetastarch, and saline solutions in patients with hypovolemic and septic shock. Crit Care Med 11:839-850
66. Roberts JA, Lipman J (2009) Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 37:840-851; quiz 59
67. McKinnon PS, Paladino JA, Schentag JJ (2008) Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 31:345-351
68. Angus BJ, Smith MD, Suputtamongkol Y, Mattie H, Walsh AL, Wuthiekanun V et al (2000) Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. Br J Clin Pharmacol 50:184-191
69. Mouton JW, den Hollander JG (1994) Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 38:931-936
70. Roosendaal R, Bakker-Woudenberg IA, van den Berghe-van Raffe M, Vink-van den Berg JC, Michel BM (1989) Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats. Eur J Clin Microbiol Infect Dis 8:878-887
71. Lodise TP Jr, Lomaestro B, Drusano GL (2007) Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 44:357-363
72. Marik PE (1993) Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth Intensive Care 21:172-173
73. Buijk SE, Mouton JW, Gyssens IC, Verbrugh HA, Bruining HA (2002) Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med 28:936-942
74. Lee J, Yoon S, Shin D, Han H, An H, Lee J et al (2014) Predictive performance of gentamicin dosing nomograms. Drug Des Devel Ther 8:1097-1106
75. Toschlog EA, Blount KP, Rotondo MF, Sagraves SG, Bard MR, Schenarts PJ et al (2003) Clinical predictors of subtherapeutic aminoglycoside levels in trauma patients undergoing once-daily dosing. J Trauma 55:255-260; discussion 60-62
76. Udy AA, Roberts JA, Lipman J (2013) Clinical implications of antibiotic pharmacokinetic principles in the critically ill. Intensive Care Med 39:2070-2082
77. Carlier M, Carrette S, Roberts JA, Stove V, Verstraete A, Hoste E et al (2013) Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? Crit Care 17:R84
78. Huttner A, Von Dach E, Renzoni A, Huttner BD, Affaticati M, Pagani L et al (2015) Augmented renal clearance, low beta-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study. Int J Antimicrob Agents 45: 385-392
79. Sime FB, Udy AA, Roberts JA (2015) Augmented renal clearance in critically ill patients: etiology, definition and implications for beta-lactam dose optimization. Curr Opin Pharmacol 24:1-6
80. Udy AA, De Waele JJ, Lipman J (2015) Augmented renal clearance and therapeutic monitoring of beta-lactams. Int J Antimicrob Agents 45:331-333
81. Udy AA, Lipman J, Jarrett P, Klein K, Wallis SC, Patel K et al (2015) Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance? Crit Care 19:28
82. Vinks AA (2002) The application of population pharmacokinetic modeling to individualized antibiotic therapy. Int J Antimicrob Agents 19:313-322
83. van Lent-Evers NA, Mathot RA, Geus WP, van Hout BA, Vinks AA (1999) Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit 21:63-73
84. Kong X, Wen JQ, Qi RF, Luo S, Zhong JH, Chen HJ et al (2014) Diffuse interstitial brain edema in patients with end-stage renal disease undergoing hemodialysis: a tract-based spatial statistics study. Medicine 93:e313
85. Gupta V, Yassin MH (2013) Infection and hemodialysis access: an updated review. Infect Disord Drug Targets 13:196-205
86. Sowinski KM, Magner SJ, Lucksiri A, Scott MK, Hamburger RJ, Mueller BA (2008) Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing. Clin J Am Soc Nephrol 3:355-361
87. Teigen MM, Duffull S, Dang L, Johnson DW (2006) Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis. J Clin Pharmacol 46:1259-1267
88. Trotman RL, Williamson JC, Shoemaker DM, Salzer WL (2005) Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 41:1159-1166
89. Plajer SM, Chin PK, Vella-Brincat JW, Buffery PJ, Begg EJ (2015) Gentamicin and renal function: lessons from 15 years' experience of a pharmacokinetic service for extended interval dosing of gentamicin. Ther Drug Monit 37:98-103
90. Capellier G, Cornette C, Boillot A, Guinchard C, Jacques T, Blasco G et al (1998) Removal of piperacillin in critically ill patients undergoing continuous venovenous hemofiltration. Crit Care Med 26:88-91
91. van der Werf TS, Mulder PO, Zijlstra JG, Uges DR, Stegeman CA (1997) Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH). Intensive Care Med 23:873-877
92. Valtonen M, Tiula E, Takkunen O, Backman JT, Neuvonen PJ (2001) Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and hae-modiafiltration in patients with acute renal failure. J Antimicrob Chemother 48:881-885
93. Mueller SC, Majcher-Peszynska J, Hickstein H, Francke A, Pertschy A, Schulz M et al (2002) Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis. Antimicrob Agents Chemother 46:1557-1560
94. Asin-Prieto E, Rodriguez-Gascon A, Troconiz IF, Soraluce A, Maynar J, Sanchez-Izquierdo JA et al (2014) Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/ pharmacodynamic analysis. J Antimicrob Chemother 69:180-189
95. Derendorf H, Dalla Costa T (1996) Pharmacokinetics of piperacillin, tazobactam and its metabolite in renal impairment. Int J Clin Pharmacol Ther 34:482-488
96. Joy MS, Matzke GR, Frye RF, Palevsky PM (1998) Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Am J Kidney Dis 31:1019-1027
97. Matzke GR, O'Connell MB, Collins AJ, Keshaviah PR (1986) Disposition of vancomycin during hemofiltration. Clin Pharmacol Ther 40:425-430
98. Matzke GR, Zhanel GG, Guay DR (1986) Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet 11:257-282
99. DelDot ME, Lipman J, Tett SE (2004) Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. Br J Clin Pharmacol 58:259-268
100. Boereboom FT, Ververs FF, Blankestijn PJ, Savelkoul TJ, van Dijk A (1999) Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients. Intensive Care Med 25:1100-1104
101. Santre C, Leroy O, Simon M, Georges H, Guery B, Beuscart C et al (1993) Pharmacokinetics of vancomycin during continuous hemodiafiltration. Intensive Care Med 19:347-350
102. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A (2006) High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 166:2138-2144
103. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC Jr, Craig WA, Billeter M et al (2009) Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy 29:1275-1279
104. Stevens GA, Singh GM, Lu Y, Danaei G, Lin JK, Finucane MM et al (2012) National, regional, and global trends in adult overweight and obesity prevalences. Popul Health Metrics 10:22
105. Ogden CL, Carroll MD, Flegal KM (2014) Prevalence of obesity in the United States. JAMA 312:189-190
106. Ogden CL, Carroll MD, Kit BK, Flegal KM (2014) Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 311:806-814
107. Han PY, Duffull SB, Kirkpatrick CM, Green B (2007) Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther 82:505-508
108. Longo C, Bartlett G, Macgibbon B, Mayo N, Rosenberg E, Nadeau L et al (2013) The effect of obesity on antibiotic treatment failure: a historical cohort study. Pharmacoepidemiol Drug Saf 22:970-976
109. Pai MP, Paloucek FP (2000) The origin of the "ideal" body weight equations. Ann Pharmacother 34:1066-1069
110. Bauer LA, Edwards WA, Dellinger EP, Simonowitz DA (1983) Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol 24:643-647
111. Schwartz SN, Pazin GJ, Lyon JA, Ho M, Pasculle AW (1978) A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects. J Infect Dis 138: 499-505
112. Korsager S (1980) Administration of gentamicin to obese patients. Int J Clin Pharmacol Ther Toxicol 18:549-553
113. Janson B, Thursky K (2012) Dosing of antibiotics in obesity. Curr Opin Infect Dis 25:634-649
114. Ortega A, Aldaz A, Giraldez J, Brugarolas A (1999) Relationship between pharmacokinetic parameters of gentamicin and patient characteristics and/or clinical data in patients with solid organ tumours. Pharm World Sci 21:227-232
115. Leader WG, Tsubaki T, Chandler MH (1994) Creatinine-clearance estimates for predicting gentamicin pharmacokinetic values in obese patients. Am J Hosp Pharm 51:2125-2130
116. Bauer LA, Blouin RA, Griffen WO Jr, Record KE, Bell RM (1980) Amikacin pharmacokinetics in morbidly obese patients. Am J Hosp Pharm 37:519-522
117. Blouin RA, Mann HJ, Griffen WO Jr, Bauer LA, Record KE (1979) Tobramycin pharmacokinetics in morbidly obese patients. Clin Pharmacol Ther 26:508-512
118. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M et al (2009) Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 49:325-327
119. Grace E (2012) Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years. J Antimicrob Chemother 67:1305-1310
120. Bauer LA, Black DJ, Lill JS (1998) Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol 54:621-625
121. Ducharme MP, Slaughter RL, Edwards DJ (1994) Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit 16:513-518
122. Vance-Bryan K, Guay DR, Gilliland SS, Rodvold KA, Rotschafer JC (1993) Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother 37:436-440
123. Leong JV, Boro MS, Winter M (2011) Determining vancomycin clearance in an overweight and obese population. Am J Health Syst Pharm 68:599-603
124. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL (2009) Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 49:507-514
125. Lodise TP, Lomaestro B, Graves J, Drusano GL (2008) Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 52:1330-1336
126. Truong J, Levkovich BJ, Padiglione AA (2012) Simple approach to improving vancomycin dosing in intensive care: a standardised loading dose results in earlier therapeutic levels. Intern Med J 42:23-29
127. Toma O, Suntrup P, Stefanescu A, London A, Mutch M, Kharasch E (2011) Pharmacokinetics and tissue penetration of cefoxitin in obesity: implications for risk of surgical site infection. Anesth Analg 113:730-737
128. Rich BS, Keel R, Ho VP, Turbendian H, Afaneh CI, Dakin GF et al (2012) Cefepime dosing in the morbidly obese patient population. Obes Surg 22:465-471
129. Mann HJ, Buchwald H (1986) Cefamandole distribution in serum, adipose tissue, and wound drainage in morbidly obese patients. Drug Intell Clin Pharm 20:869-873
130. Ho VP, Nicolau DP, Dakin GF, Pomp A, Rich BS, Towe CW et al (2012) Cefazolin dosing for surgical prophylaxis in morbidly obese patients. Surg Infect (Larchmt) 13:33-37
131. Chen M, Nafziger AN, Drusano GL, Ma L, Bertino JS Jr.(2006) Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob Agents Chemother 50:1222-1227
132. Zakrison TL, Hille DA, Namias N (2012) Effect of body mass index on treatment of complicated intra-abdominal infections in hospitalized adults: comparison of ertapenem with piperacillin-tazobactam. Surg Infect (Larchmt) 13:38-42
133. Cheatham SC, Fleming MR, Healy DP, Chung EK, Shea KM, Humphrey ML et al (2014) Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit. J Clin Pharmacol 54:324-330
134. Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW (1976) The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol 31:155-163
135. Davies DF, Shock NW (1950) Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest 29:496-507
136. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461-470
137. Greenblatt DJ, Divoll M, Abernethy DR, Shader RI (1982) Physiologic changes in old age: relation to altered drug disposition. J Am Geriatr Soc 30:S6-S10
138. Greenblatt DJ, Sellers EM, Shader RI (1982) Drug therapy: drug disposition in old age. N Engl J Med 306:1081-1088
139. Pucino F, Beck CL, Seifert RL, Strommen GL, Sheldon PA, Silbergleit IL (1985) Pharmacogeriatrics. Pharmacotherapy 5:314-326
140. Wallace S, Whiting B (1976) Factors affecting drug binding in plasma of elderly patients. Br J Clin Pharmacol 3:327-330
141. Marangos MN, Skoutelis AT, Nightingale CH, Zhu Z, Psyrogiannis AG, Nicolau DP et al (1995) Absorption of ciprofloxacin in patients with diabetic gastroparesis. Antimicrob Agents Chemother 39:2161-2163
142. Ebbesen J, Buajordet I, Erikssen J, Brors O, Hilberg T, Svaar H et al (2001) Drug-related deaths in a department of internal medicine. Arch Intern Med 161:2317-2323
143. Hohl CM, Dankoff J, Colacone A, Afilalo M (2001) Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med 38:666-671
144. Jorgensen T, Johansson S, Kennerfalk A, Wallander MA, Svardsudd K (2001) Prescription drug use, diagnoses, and healthcare utilization among the elderly. Ann Pharmacother 35:1004-1009
145. Faulkner CM, Cox HL, Williamson JC (2005) Unique aspects of antimicrobial use in older adults. Clin Infect Dis 40:997-1004
146. Biggs WS (2003) Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients. J Am Board Fam Pract 16:455-457
147. Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH (2002) Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents. Am J Med 113:232-234
148. Amankwa K, Krishnan SC, Tisdale JE (2004) Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors. Clin Pharmacol Ther 75:242-247
149. Black FO, Pesznecker SC (1993) Vestibular ototoxicity. Clinical considerations. Otolaryngol Clin North Am 26:713-736
150. Gatell JM, Ferran F, Araujo V, Bonet M, Soriano E, Traserra J et al (1987) Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides. Antimicrob Agents Chemother 31:1383-1387
151. Mahmood I (2014) Dosing in children: a critical review of the pharmacokinetic allometric scaling and modelling approaches in paediatric drug development and clinical settings. Clin Pharmacokinet 53:327-346
152. Mahmood I (2007) Prediction of drug clearance in children: impact of allometric exponents, body weight, and age. Ther Drug Monit 29:271-278
153. Cella M, Knibbe C, Danhof M, Della Pasqua O (2010) What is the right dose for children? Br J Clin Pharmacol 70:597-603
154. Sy SK, Asin-Prieto E, Derendorf H, Samara E (2014) Predicting pediatric age-matched weight and body mass index. AAPS J 16:1372-1379
155. Hu TM, Hayton WL (2001) Allometric scaling of xenobiotic clearance: uncertainty versus universality. AAPS Pharm Sci 3:E29
156. Jensen PD, Edgren BE, Brundage RC (1992) Population pharmacokinetics of gentamicin in neonates using a nonlinear, mixed-effects model. Pharmacotherapy 12:178-182
157. Botha JH, du Preez MJ, Adhikari M (2003) Population pharmacokinetics of gentamicin in South African newborns. Eur J Clin Pharmacol 59:755-759
158. Vervelde ML, Rademaker CM, Krediet TG, Fleer A, van Asten P, van Dijk A (1999) Population pharmacokinetics of gentamicin in preterm neonates: evaluation of a once-daily dosage regimen. Ther Drug Monit 21:514-519
159. Zakova M, Pong S, Trope A, Atenafu EG, Papaioannou V, Bitnun SA et al (2014) Dose derivation of once-daily dosing guidelines for gentamicin in critically ill pediatric patients. Ther Drug Monit 36:288-294
160. Mohamed AF, Nielsen EI, Cars O, Friberg LE (2012) Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants. Antimicrob Agents Chemother 56:179-188
161. Haughey DB, Hilligoss DM, Grassi A, Schentag JJ (1980) Two-compartment gentamicin pharmacokinetics in premature neonates: a comparison to adults with decreased glomerular filtration rates. J Pediatr 96:325-330
162. Landers S, Berry PL, Kearns GL, Kaplan SL, Rudolph AJ (1984) Gentamicin disposition and effect on development of renal function in the very low birth weight infant. Dev Pharmacol Ther 7:285-302
163. Sherwin CM, Svahn S, Van der Linden A, Broadbent RS, Medlicott NJ, Reith DM (2009) Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis. Eur J Clin Pharmacol 65:705-713
164. Ikawa K, Morikawa N, Ikeda K, Miki M, Kobayashi M (2010) Population pharmacokinetics and pharmacodynamics of meropenem in Japanese pediatric patients. J Infect Chemother 16:139-143
165. Bradley JS, Sauberan JB, Ambrose PG, Bhavnani SM, Rasmussen MR, Capparelli EV (2008) Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate. Pediatr Infect Dis J 27:794-799